$DNLI News

Denali Therapeutics: Bullish On Avlayah And Their Prospects

Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One

Denali Therapeutics (NASDAQ:DNLI) Shows Perfect Technical Setup for a Breakout

UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation

Denali Therapeutics (NASDAQ:DNLI) Drops as Q2 AVLAYAH Revenue Misses Estimates

Denali Therapeutics Q2 EPS $(0.68) Misses $(0.65) Estimate, Sales $3.604M Miss $14.613M Estimate

Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36

Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35

JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target

Denali Therapeutics Signs Deal To Sell Its Rare Pediatric Disease Priority Review Voucher For $195M

Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data

Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35

Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $40

Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target

Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $23

Denali Therapeutics Q1 EPS $(0.69) Beats $(0.71) Estimate